90% of primitive juvenile granulocytes are due to acute myeloid leukemia.
Primordial myeloid cells usually refer to the promyelocytes in the bone marrow, and the normal value range of the percentage of promyelocytes in the bone marrow smear of a normal person is 1.51%~1.63%. The percentage of promyelocytes 90% is significantly higher than the normal value range, which is the manifestation of acute myeloid leukemia type M3 (i.e. acute promyelocytic leukemia).
Patients with this disease are often associated with PML-RARĪ± fusion gene expression, and t(15;17) gene mutation is seen in chromosomal karyotype analysis. The fusion gene, chromosomal karyotype analysis, bone marrow biopsy and other tests can be further improved to clarify the diagnosis.
Patients with acute promyelocytic leukemia are prone to serious complications such as disseminated intravascular coagulation during the early stage of the disease and during the first induced differentiation treatment, which can easily lead to serious bleeding complications, such as gastrointestinal hemorrhage, intracranial hemorrhage, etc., and the condition of the patients is critical.
Acute promyelocytic leukemia can be completely cured through active induction and differentiation therapy (arsenic trioxide + retinoic acid tablets double induction and differentiation therapy). It is recommended that the patient go to the Department of Hematology in time for consultation, and after the diagnosis is clear, the patient will be treated in time with targeted therapy under the guidance of the physician.